Patents Represented by Attorney, Agent or Law Firm Kimberlin L. Morley
-
Patent number: 6664054Abstract: The present invention provides the art with the DNA coding sequences of polynucleotides that are up- or down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.Type: GrantFiled: January 31, 2001Date of Patent: December 16, 2003Assignee: Chiron CorporationInventor: Guilia C. Kennedy
-
Patent number: 6599706Abstract: Methods and materials are disclosed for the production of purified, active recombinant human neutrophil protease, PR-3, via activation of a pro-form herein referred to as proPR-3. Human PR-3 is useful for discovering inhibitors of excessive release of mature, active TNF&agr;. Also disclosed are methods for the identification of inhibitors of the conversion of the pro-form of TNF&agr; to its mature active form.Type: GrantFiled: June 7, 1995Date of Patent: July 29, 2003Assignee: Chiron CorporationInventors: Robert F. Halenbeck, Michael Kriegler, Jan Tuttleman, Carl Perez, David A. Jewell, Kirston E. Koths
-
Patent number: 6589745Abstract: A human gene termed CIF130 and its expression products can alter the spatial or temporal patterns of mitosis or cell cycle progression of a human cell. Methods of treating disorders involving alterations in the regulation of mitosis or cell cycle progression utilize the gene and its expression product. Genes whose expression is dependent upon CIF130 expression can be identified.Type: GrantFiled: May 15, 2002Date of Patent: July 8, 2003Assignee: Chiron CorporationInventor: Joerg Kaufmann
-
Patent number: 6586244Abstract: Inhibitors of laminin5beta3 are provided that reduce the expression or biological activities of laminin5beta3 or the expression of laminin5beta3 mRNA in a mammalian cell. Laminin5beta3 inhibitors include antisense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. Laminin5beta3 inhibitors find use in compositions and methods for decreasing laminin5beta3 gene expression as well as methods for inhibiting the proliferation of mammalian cells, including tumor cells of epithelial origin, and methods for treating neoplastic diseases.Type: GrantFiled: June 6, 2001Date of Patent: July 1, 2003Assignee: Chiron CorporationInventors: Christoph J. Reinhard, Anne B. Jefferson, Douglas R. Den-Otter, Jill A. Winter
-
Patent number: 6566063Abstract: The invention features methods for detection of metastatic and potentially metastatic cancerous cells by detection of expression of a gland-specific Ets transcription factor (GSEF) sequence, which encodes an Ets-domain containing protein. The invention also features methods and compositions for modulation of the polypeptide and/or gene activity for prophylactic and therapeutic purposes, such as inhibition of progression of a cell to a metastatic cancerous cell.Type: GrantFiled: May 12, 2000Date of Patent: May 20, 2003Assignee: Chiron CorporationInventors: Joerg Kaufmann, Hong Xin, Greg Harrowe
-
Patent number: 6492112Abstract: A human gene encoding a novel mitogen-activated (MAP) kinase kinase, MKK7, provides methods and reagents for treating a variety of MKK7-mediated disorders, such as ischemic heart disease, kidney failure, oxidative liver damage, respiratory distress syndrome, heat and radiation burns, septic shock, autoimmune disorders, and inflammatory diseases. MKK7 reagents can also be used to induce or prevent apoptosis.Type: GrantFiled: December 7, 1998Date of Patent: December 10, 2002Assignee: Chiron CorporationInventors: Christoph Reinhard, Altaf Kassam, David Pot
-
Patent number: 6489137Abstract: Methods are provided for assessing mutations and/or loss of the huBUB1 gene in human tumors. Loss of wild-type huBUB1 genes is involved in neoplastic development. Therapeutic regimens can be planned on the basis of the mutational status of huBUB1.Type: GrantFiled: June 11, 1998Date of Patent: December 3, 2002Assignee: Chiron CorporationInventor: Todd W. Seeley
-
Patent number: 6476207Abstract: This invention relates to novel human genes, to proteins expressed by the genes, and to variants of the proteins. The invention also relates to diagnostic and therapeutic agents related to the genes and proteins, including probes, antisense constructs, and antibodies. The invention further relates to polynucleotides differentially expressed in prostate cancer.Type: GrantFiled: June 9, 1999Date of Patent: November 5, 2002Assignee: Chiron CorporationInventors: Jimmy Zhang, Jon H. Astle, Eddie Carroll, III, Wilson O. Endege, Donna M. Ford, John E. Monahan, Robert Schlegel, Kathleen E. Steinmann
-
Patent number: 6468790Abstract: Gene sequences as shown in SEQ ID NOS:1-85 have been found to be significantly associated with metastatic potential of cancer cells, especially breast and colon cancer cells. Methods are provided for determining the risk of metastasis of a tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS:1-85, or a substantial portion thereof.Type: GrantFiled: November 13, 2000Date of Patent: October 22, 2002Assignee: Chiron CorporationInventor: Klaus Giese
-
Patent number: 6465231Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3&agr; and GSK3&bgr; polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: GrantFiled: July 25, 2001Date of Patent: October 15, 2002Assignee: Chiron CorporationInventors: Stephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
-
Patent number: 6448379Abstract: Inhibitors, including antibodies, of IL8 binding to its receptors, that interact with the amino-terminal extracellular domain of the IL8 receptor and which compete with IL8 for receptor-binding, are disclosed. The inhibitors are useful modulators of IL8 receptor-mediated biological activity.Type: GrantFiled: September 14, 1993Date of Patent: September 10, 2002Assignee: Chiron CorporationInventors: Patricia Tekamp-Olson, Guy Mullenbach, Mary Ellen Wernette-Hammond
-
Patent number: 6432668Abstract: A human gene encoding a novel cyclin-dependent kinase termed hPFTAIRE and its expression products can be used to provide reagents and methods for detecting migrating or metastasizing cells. Compositions and methods for treating proliferative disorders and neoplasia are also provided.Type: GrantFiled: December 7, 1998Date of Patent: August 13, 2002Assignee: Chiron CorporationInventors: Christoph Reinhard, David Pot, Altaf Kassam, Tasha Marenbach, Lewis T. Williams
-
Patent number: 6429302Abstract: The present invention is based on the discovery of polynucleotides that represent novel genes that are differentially expressed in pancreatic disease, e.g., pancreatic cancer, dysplasia, pancreatitis, or diabetes. The invention features methods of identifying cells affected by such pancreatic diseases by detection of a gene product encoded by such differentially expressed genes, as well as methods of modulating expression of such gene products to effect therapy (e.g., to decrease growth and/or affect abnormal characteristics of cancerous or dysplastic pancreatic cells.Type: GrantFiled: January 25, 2000Date of Patent: August 6, 2002Assignee: Chiron CorporationInventor: Giulia Kennedy
-
Patent number: 6423822Abstract: A human gene termed CIF130 and its expression products can alter the spatial or temporal patterns of mitosis or cell cycle progression of a human cell. Methods of treating disorders involving alterations in the regulation of mitosis or cell cycle progression utilize the gene and its expression product. Genes whose expression is dependent upon CIF130 expression can be identified.Type: GrantFiled: November 9, 2000Date of Patent: July 23, 2002Assignee: Chiron CorporationInventor: Joerg Kaufmann
-
Patent number: 6414120Abstract: Mammalian deep orange tumor suppressor genes are disclosed. Mammalian deep orange genes and proteins can be used as therapeutics, as diagnostic tools, and in making animal models. The genes can be used to identify a q13 region of a human chromosome 15 and a central region of a mouse chromosome 2.Type: GrantFiled: March 3, 2000Date of Patent: July 2, 2002Assignee: Chiron CorporationInventor: Filippo M. Randazzo
-
Patent number: 6410312Abstract: Methods are provided for assessing mutations and/or loss of the huBUB3 gene in human tumors. Loss of wild-type huBUB3 genes is involved in neoplastic development. Therapeutic regimens can be planned on the basis of the mutational status of huBUB3.Type: GrantFiled: December 10, 1998Date of Patent: June 25, 2002Assignee: Chiron CorporationInventor: Todd W. Seeley
-
Patent number: 6322779Abstract: The present invention is directed to an isolated and purified, recombinant, unglycosylated and dimeric CSF-1, the dimeric CSF-1 being biologically active and essentially endotoxin and pyrogen-free, the dimeric CSF-1 consisting essentially of two monomeric human CSF-1 subunits. The present invention is further directed to pharmaceutical compositions comprising the same.Type: GrantFiled: June 7, 1995Date of Patent: November 27, 2001Assignee: Chiron CorporationInventors: Robert Halenbeck, Kirston Koths, Cynthia Cowgill, Walter J. Laird
-
Patent number: 6303372Abstract: A human gene termed CIF130 and its expression products can alter the spatial or temporal patterns of mitosis or cell cycle progression of a human cell. Methods of treating disorders involving alterations in the regulation of mitosis or cell cycle progression utilize the gene and its expression product. Genes whose expression is dependent upon CIF130 expression can be identified.Type: GrantFiled: June 11, 1999Date of Patent: October 16, 2001Assignee: Chiron CorporationInventor: Joerg Kaufmann
-
Patent number: 6300484Abstract: The present invention is a novel nucleic acid sequence which hybridizes to SEQ ID NO:6 or fragments thereof under stringent conditions, or fragments thereof. The invention also includes diagnostic assays, expression vectors, control sequences, antisense molecule, ribozymes, and host cells to express the polypeptide encoded by the nucleic acid sequence. The present invention also includes claims to the polypeptide sequence coded by the nucleic acid sequences.Type: GrantFiled: September 30, 1998Date of Patent: October 9, 2001Assignee: Chiron CorporationInventor: David Duhl
-
Patent number: 6300485Abstract: The present invention discloses the amino acid and nucleic acid sequences of a new CNGC and Myosin that map to the region of the human chromosome associated with Bardet-Biedl Syndrome. Cyclic nucleotide gated channels (CNGCs) comprise a family of multimeric protein ion channels that open in response to the binding of a cyclic nucleotide to an intracellular domain. The two new proteins, CNGC-15 and Myosin IXa, are useful in the study, diagnosis and treatment of Bardet-Biedl Syndrome and Usher Syndrome. Other indications that can be treated by CNGC-15 and/or Myosin IXa polypeptides, or agonists or antagonists include hearing loss, retinis pigmentosa, obesity, hypogonadism, sterility, polydactyly, brachydactyly, syndactyly, mental retardation, renal abnormalities, hypertension, diabetes and cardiovascular abnormalities. Compositions and methods for expressing cyclic nucleotide gated channel-15 (CNGC-15) and Myosin IXa are provided.Type: GrantFiled: October 14, 1998Date of Patent: October 9, 2001Assignee: Chiron CorporationInventors: Arwen E. Adams, Choi Ying Chiu, David Duhl, Susan W. Gorman, Song Leng, Val Sheffield, Juliet Welch